Showing 6891-6900 of 8468 results for "".
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- Study: Dupilumab Shows Sustained Benefit for Severe ADhttps://practicaldermatology.com/news/study-dupilumab-shows-sustained-benefit-severe-ad/2467337/New research on the long-term safety and efficacy of dupilumab in adults with moderate to severe atopic dermatitis (AD) indicates that dupilumab was safe and effective in the long-term treatment of the condition. The open-label extension study was conducted over a period of 5 years in 28
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Platelet-Rich Plasma Improves Outcomes in Severe ADhttps://practicaldermatology.com/news/platelet-rich-plasma-improves-outcomes-severe-ad/2467268/A new study looking at platelet-rich plasma (PRP) as an adjuvant therapy for adult atopic dermatitis (AD) suggested the treatment was associated with favorable outcomes. The literature search focused on original English-language articles about PRP as a therapeutic method for adult AD. Revi
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Survey: Just 40% See Dermatologists Annually Despite Skin Concernshttps://practicaldermatology.com/news/survey-just-40-see-dermatologists-annually-despite-skin-concerns/2467226/Manufacturer CeraVe has announced findings from a new survey suggesting that while 80% of participants experienced skin concerns, just 40% of them visited a dermatologist for an annual skin exam. The survey of 1,000 American adults also revealed that 25% suffered from serious skin condit